Search This Blog

Friday, June 10, 2016

Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine

Chronic Migraine Study Meets Primary Endpoint, Demonstrating Efficacy and Safety of Erenumab in Patients With Chronic Migraine Over 12 Weeks of Treatment
Erenumab Co-Developed by Amgen and Novartis


Amgen - Investors - RSS Content
Posted by at
Labels:

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)